1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 15,000 | 15,300 | 20:13 | |
| 15,000 | 15,300 | 17:12 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Fortrea Holdings Inc: Fortrea übernimmt Einheit für klinische Pharmakologie und bioanalytische Laboraktivitäten von Worldwide Clinical Trials | 438 | GlobeNewswire (Deutschland) | Erweiterung der bioanalytischen Kapazitäten und Ausbau des Netzwerks für die frühe klinische Entwicklung von Fortrea - Worldwide treibt zugleich seine Wachstumsstrategie in der klinischen Entwicklung... ► Artikel lesen | |
| Mi | Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion | 1 | Benzinga.com | ||
| FORTREA Aktie jetzt für 0€ handeln | |||||
| Mi | Fortrea To Acquire Early Phase Services Business From Worldwide In Deal Valued At Approx. $45 Mln | 1 | RTTNews | ||
| Mi | Fortrea to acquire Worldwide's early phase unit for $45 million | 5 | Investing.com | ||
| Mi | Fortrea Holdings Inc: Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials | 423 | GlobeNewswire (Europe) | Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership... ► Artikel lesen | |
| 11.08. | Fortrea (FTRE) Gains Traction in Turnaround | 1 | Insider Monkey | ||
| 29.07. | Evercore ISI hebt Kursziel für Fortrea wegen Turnaround-Erfolgs auf 25 US-Dollar an | 4 | Investing.com Deutsch | ||
| 29.07. | Evercore ISI raises Fortrea stock price target to $25 on turnaround | 1 | Investing.com | ||
| 29.07. | Fortrea Holdings beats top-line and bottom-line estimates; raises FY26 outlook | 3 | Seeking Alpha | ||
| 29.07. | Fortrea Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.07. | Fortrea Holdings Inc: Fortrea Reports Second Quarter 2026 Results | 664 | GlobeNewswire (Europe) | Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance Highlights For the three months ended June 30, 2026: Revenues of $678.2... ► Artikel lesen | |
| 14.07. | Fortrea Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.06. | Fortrea Holdings Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.06. | Fortrea names Jason Knoblauch as CFO, reaffirms 2026 guidance | 1 | Investing.com | ||
| 26.06. | Fortrea names Jason Knoblauch as CFO | 3 | Seeking Alpha | ||
| 26.06. | Fortrea Reiterates FY26 Guidance, Targeting Revenues In Range Of $2.550B-$2.650B Vs $2.594B Est., And Adjusted EBITDA Of $190M-$220M | 1 | Benzinga.com | ||
| 26.06. | Fortrea Appoints Jason Knoblauch To Succeed Jill McConnell As CFO | 4 | RTTNews | ||
| 26.06. | Fortrea Holdings Inc: Fortrea Names Jason Knoblauch as Chief Financial Officer | 986 | GlobeNewswire (Europe) | DURHAM, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Jason Knoblauch has been appointed... ► Artikel lesen | |
| 12.06. | Fortrea Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.06. | Fortrea Holdings Inc: Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 57,70 | -1,20 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| QIAGEN | 36,340 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| AMGEN | 358,90 | -4,65 % | AKTIEN IN FOKUS: Herzmittel-Flop drückt Novartis - Auch Ionis und Amgen schwach | ZÜRICH (dpa-AFX) - Der Misserfolg mit dem Herzmedikament Pelacarsen setzt am Montag gleich mehrere Aktien unter Druck. Zum einen die des Entwicklers Ionis Pharma und des Lizenznehmers Novartis und... ► Artikel lesen | |
| NOVAVAX | 8,760 | -0,34 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| STRYKER | 260,80 | -0,08 % | Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center | SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information
Stryker announced the successful completion of the first... ► Artikel lesen | |
| ILLUMINA | 187,58 | -0,15 % | S&P Dow Jones Indices: Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 | NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,455 | -1,16 % | Cathie Wood Says AI Revolution Could Supercharge Global Growth - TSLA, COIN and CRSP Stocks Are Among Her Top Bets | ||
| OCUGEN | 1,200 | +2,04 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,440 | +4,19 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 56,50 | +1,55 % | Cathie Wood's weekly recap: loads Rocket Lab, Block; cuts Palantir, Tempus AI | ||
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| DEFENCE THERAPEUTICS | 0,314 | -0,95 % | Defence Therapeutics Inc.: Defence Therapeutics Provides Updates on Sharing Agreement | Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| EDITAS MEDICINE | 2,840 | +2,90 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,368 | -2,24 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,393 | -2,96 % | Breaking News: Forschungskapital, FDA-Weg und Börsenupgrade?! |
FORTREA HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 14,800 Euro und damit -5,13 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTREA HOLDINGS INC finden Sie auf Wallstreet Online.